Welcome!

News Feed Item

Vaccine Manufacturing Technology and Services: World Market Forecast 2014-2024

LONDON, March 19, 2014 /PRNewswire/ --


Prospects  For  Leading  Players

Vaccine  manufacturing  technology  and  services  -  your  guide  to  trends  and  revenue  prospects  for  vaccine  production

What's the outlook for producing vaccines? Visiongain's brand new report shows you the potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 205 page report provides 104 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market, submarket and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions.

There's rising demand for those products and services. In particular, outsourced vaccine manufacturing will expand from 2014 to 2024, with growing revenues.

Forecasts  from  2014-2024  and  other  analyses  show  you  commercial  prospects

Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT), company profiles and commercial developments. Read the full transcript of four exclusive expert opinion interviews from an industry specialist informing your understanding and allowing you to assess prospects for investments and sales:
- Dr. Eluemuno Blyden, CEO and Founder, AfriVax
- Chris Redmond, GMP and nonGMP Sales Manager, Ambiopharm
- Dr. Victor Van Cleave, Vice President of Contract Manufacturing & Research and Development (R&D), Meridian Life Science
- Dr. Stefan Beyer, Managing Director, Vibalogics

You  will  find  prospects  for  key  submarkets

In addition to analyses of the overall world market, you will see revenue forecasting for these five world-level vaccine submarkets to 2024:
-    Paediatric vaccines
-    Influenza vaccines
-    Adult prophylactic vaccines
-    Therapeutic vaccines
-    Contract vaccine manufacturing

Our investigation shows business research and analysis with individual revenue forecasts and discussions. Which vaccine submarket will generate the most revenues? How will the vaccine contract manufacturing market expand? This study will allow you to thoroughly understand the industry, finding the most promising places for investments and sales.

To see an exec summary of this report please email Sara Peerun on sara.peerun@visiongainglobal.com

What  are  the  prospects  for  vaccine  contract  manufacturing  in  the  leading  regions  and  countries?

Events and progress worldwide will influence the market, especially outsourced vaccine manufacturing in emerging countries.

In our study you will find individual revenue forecasts to 2024 for 11 vaccine contract manufacturing national markets:
-    US
-    Japan
-    Germany
-    Italy
-    Spain
-    France
-    UK
-    Russia
-    China
-    India
-    Brazil
-    RoW

Many opportunities exist within the vaccines contract manufacturing market. Greater uptake of existing technology and products worldwide will also stimulate the industry and market. With our new investigation you will gain business research and analysis with individual sales predictions and discussions. You will find analysis of competition, as well as commercial drivers and restraints. See what is likely to achieve the most success.

Leading  companies  and  potential  for  market  growth

Overall world revenue for the vaccines contract manufacturing market will reach $705.62m in 2014, our study forecasts. We predict strong revenue growth from 2014 to 2024. Our research shows you what organisations hold greatest potential. See profiles of 10 leading companies, including these:
-    Baxter BioPharma Solutions
-    Boehringer Ingelheim
-    Catalent
-    Charles River Laboratories
-    IDT Biologika GmbH
-    Lonza
-    Meridian Life Science
-    Sigma-Aldrich
-    SynCo Bio Partners
-    OSO BioPharmaceuticals Manufacturing

In general, a company profile gives you the following information:
-    Overview of the company
-    Discussion of a company's activities and outlook including descriptions of leading products
-    Recent financial results
-    Assessment of recent developments - mergers and acquisitions (M&A),  new products, and collaborations, inc. alliances, partnerships and joint ventures

To see an exec summary of this report please email Sara Peerun on sara.peerun@visiongainglobal.com

What  issues  will  affect  the  vaccine  contract  manufacturing  market?

Our new report discusses issues and events affecting the vaccine contract manufacturing market. You will find discussions, including qualitative analyses:
-    Healthy pipeline of vaccine products
-    Cell-based techniques - mammalian cell lines, avian-derived cells, plant-based processes and other methods
-    Pandemic preparedness
-    Pricing, regulation and government policy
-    Perception of risk in outsourcing vaccine manufacturing

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How  the Vaccine  Manufacturing  Technology  and  Services:  World  Market  Forecast  2014-2024:  Prospects  For  Leading  Players  report  helps  you

In summary, our 205 page report gives you the following knowledge:
-    Revenues forecasts to 2024 for the overall world vaccine market and 5 submarkets - discover the industry's prospects, finding promising places for investments and revenues
-    Assessment of  10 leading companies, and others, discovering their activities and outlooks
-    Market forecasting to 2024 for 11 leading national vaccine contract manufacturing markets - USA, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India, China and RoW
-    View opinions from our survey, seeing 4 interviews with leading authorities
-    Investigation of competition and opportunities influencing sales
-    Discussion of what stimulates and restrains the vaccine contract manufacturing market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information  found  nowhere  else

With our survey you are less likely to fall behind in knowledge or miss opportunities. See how our report could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the vaccines market and vaccine contract manufacturing market. You will find data, trends and predictions. Please order our report now.

To request an exec summary of this report please email Sara Peerun at            sara.peerun@visiongainglobal.com or call Tel : +44 (0) 20 7336 6100

Or click on http://www.visiongain.com/Report/1221/Vaccine-Manufacturing-Technology-and-Services-World-Market-Forecast-2014-2024

Companies  Listed  in  this  report:

AAI Pharma Services Corp.
AbbVie
Accugenix
Activaris Biotech
Adamis Pharmaceuticals
Aduro Biotech
Advanced Bioscience Laboratories, Inc.
Advaxis
AFFiRis
Afrivax
Agenus
ALK- Abello
Alpha Biologics
AlphaVax
Althea Technologies, Inc.
Ambiopharm
Amgen
AmProtein
Antigen Express
Antigenics
Aptuit CTS
Argos Therapeutics
Artelis
AstraZeneca
 ATMI
ATMI LifeSciences
AuRx
Avista Capital Partners
Batavia
Bavarian Nordic
Baxter
Baxter BioPharma Solutions
Bayer
Bayer Healthcare
Bayhill Therapeutics
Beijing Tiantan Biological Products
Bellicum Pharmaceuticals
Ben Venue Laboratories
Bend Research
Berna Biotech
Bharat Biotech International
Binnopharm
Biofabri
BioKangtai
Biological E. Serum Institute
Biomay
Biondvax
Bionor Pharma
BioReliance
BioSante Pharmaceuticals
Biovest International
Biovian
BN ImmunoTherapeutics
Boehringer Ingelheim
Bosch
Cadila Pharmceuticals
Cancer Advances
Cardinal Health
Catalent
Catalent (Shanghai) Clinical Trial Supplies
Catalent Pharma Solutions
CatScl
Celldex Therapeutics
Cellexus Limited
CEL-SCI
Celtic Pharma
Cerebricon
CG Therapeutics
Charles River Biopharmaceutical Services
Charles River Laboratories
Chengdu Institute of Biological Products
China National Biotech Corporation
Chiron B.V
Circassia
CMC Biologics
Cobra Biologics
Colby Pharmaceutical
Cook Pharmica
Corden Pharma
Covance
Crucell
CSL Biologicals
Cytos Biotechnology
Cytovance Biologics
Daiichi Sankyo
Dalian Hissen Bio-Pharm
DBV Technologies
Dendreon
DSM Biologics
Dynport Vaccine
EMD Serono
Emergent BioSolutions
Endocyte
Etubics
Eurogentec Biologics
FiberCell
Frazier Healthcare
Fujifilm Diosynth Biotechnologies
Galena
Gcon
GE Healthcare Life Sciences
GE Wave Biotech
GeneCure Biotechnologies
Genetic Immunity
Genocea Biosciences
GenPhar
GenVec
GeoVax
GlaxoSmithKline Biologicals
Gliknik
Globelmmune
Goodwin Biotechnology Inc.
Gradalis
Grand River Aseptic Manufacturing
GSK
Hawaii Biotech
Heat Biologics
Hospira
HTD Biosystems
iBio
IDT Biologika GmbH
immatics biotechnologies
Immune Response Biopharma
Immune Targeting Systems
Immunitor
ImmunoCellular Therapeutics
ImmunoFrontier
Immunomic Therapeutics
Immunotope
Immunovaccine
Immunovative Therapies
ImmunsanT
ImVisioN Therapeutics
Innogenetics Biologicals
Inovio Pharmaceuticals
Intercell Corporation
Inviragen
Invitrogen
Irvine Scientific
Janssen Alzheimer Immunotherapy
Japan Vaccine Co
Jennerex
JHP Pharmaceuticals
JN-International Medical
Johnson & Johnson
Jubilant HollisterStier
Kuhner
Leidos
LG Life Sciences
LigoCyte Pharmaceuticals
Liquidia Technologies
Lonza
MabVax Therapeutics
Medicago
MedImmune
Meisser Filtration
Memgen
Merck
Merck Serono
Meridian Life Science
Millipore
Mitsubishi Tanabe Pharma
MorphoSys
MP Biomedicals
NanoBio
Nanotherapeutics
Nascent Biologics
NewLink Genetics
Northwest Biotherapeutics
Novadigm Therapeutics
Novartis
Novartis Vaccines and Diagnostics
NovaRX
Novasep
Novavax
OncoPep
Oncothyreon
Opal Therapeutics
Opexa Therapeutics
Optimer Biotechnology
Orban Biotech
Organon Teknika Corporation
OSO Biopharmaceuticals Manufacturing
Pall Life Sciences
Pantec
Paragon Bioservices
Patheon
PaxVax
PBS Biotech
Penn Pharma
Pfizer (Wyeth Pharmaceuticals)
Pfrenex
PharmAthene
Philip Morris International
Piedmont Research Center
Pierre-Guérin Biolafitte
Pique Therapeutics
Polynoma
Prima Biomed
ProBioGen
Profectus BioSciences
Protein Sciences Corporation
Rame-Hart Sanovo
Refine Technology
Riemser Pharma GmbH
Roche
SAFC
Sanaria
Sanofi Pasteur
Sanofi Pasteur MSD
Sartorius Stedim Biotech
Selecta Biosciences
Selecta RUS
Shanghai Sunway Biotech
ShangPharma Corporation  
Shantha Biotech
Sigma Aldrich
Soligenix
Stallergenes
Stemline Therapeutics
Sumagen
Sunovion Pharmaceuticals
Synco Bio Partners
Takeda
TapImmune
TD Vaccines
Theraclone Sciences
Thermo Fisher scientific
Thymon
Transgene
TVAX Biomedical
United Biomedical
Vaccine Technologies
Vaccinogen
Vaxart
VaxInnate
VaxOnco
Vibalogics
Vivalis
Waisman Biomanufacturing
Wave Biotech
Xcellerex
Xencor
ZellWerk
Zhangjiang Biotech & Pharmaceutical Base
Zhejiang Jiang Yuan Tang Biotechnology Corporation

Other Organisations Mentioned in This Report

Aaron Diamond AIDS Research Center
Aeras Global TB Vaccine Foundation
Agência Nacional de Vigilância Sanitária (ANVISA)
Centers for Disease Control and Prevention CDC (US)
Chinese State Food and Drug Administration (SFDA)
Defense Advanced Researched Projects Agency (DAPRA)
Emory University
European Medicines Agency (EMA)
Executive European Commission (European Union)
Health Canada
Hospital Clínic de Barcelona
Infectious Disease Research Institute (IDRI)
International AIDS Vaccine Initiative (IAVI)
Ministry of Industry and Trade (Russia)
Murdoch Childrens Research Institute
National Institute of Health (US)
PATH
Research Foundation for Microbial Diseases of Osaka University
The Department of Health and Human Services (HHS) (US)
The Drug Enforcement Administration (DEA) (US)
The Food and Drug Administration (FDA) (Korean)
The Food and Drug Administration (FDA) (US)
The National Institute of Allergy and Infectious Diseases (NIAID)
The U.S. Department of Health and Human Services Office of Biomedical Advanced Research and Development Authority (BARDA)
The United Nation Industrial Development Organisation (UNIDO)
US Naval Medical Research Center
Vaccine Manufacturers Associations (India)
World Health Organisation (WHO)

To see an exec summary of this report please email Sara Peerun on sara.peerun@visiongainglobal.com


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
IT organizations are moving to the cloud in hopes to approve efficiency, increase agility and save money. Migrating workloads might seem like a simple task, but what many businesses don’t realize is that application migration criteria differs across organizations, making it difficult for architects to arrive at an accurate TCO number. In his session at 21st Cloud Expo, Joe Kinsella, CTO of CloudHealth Technologies, will offer a systematic approach to understanding the TCO of a cloud application...
DevOps at Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to w...
For financial firms, the cloud is going to increasingly become a crucial part of dealing with customers over the next five years and beyond, particularly with the growing use and acceptance of virtual currencies. There are new data storage paradigms on the horizon that will deliver secure solutions for storing and moving sensitive financial data around the world without touching terrestrial networks. In his session at 20th Cloud Expo, Cliff Beek, President of Cloud Constellation Corporation, d...
Most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes a lot of work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reduction in cost ...
"With Digital Experience Monitoring what used to be a simple visit to a web page has exploded into app on phones, data from social media feeds, competitive benchmarking - these are all components that are only available because of some type of digital asset," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
SYS-CON Events announced today that Secure Channels, a cybersecurity firm, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Secure Channels, Inc. offers several products and solutions to its many clients, helping them protect critical data from being compromised and access to computer networks from the unauthorized. The company develops comprehensive data encryption security strategie...
From 2013, NTT Communications has been providing cPaaS service, SkyWay. Its customer’s expectations for leveraging WebRTC technology are not only typical real-time communication use cases such as Web conference, remote education, but also IoT use cases such as remote camera monitoring, smart-glass, and robotic. Because of this, NTT Communications has numerous IoT business use-cases that its customers are developing on top of PaaS. WebRTC will lead IoT businesses to be more innovative and address...
Connecting to major cloud service providers is becoming central to doing business. But your cloud provider’s performance is only as good as your connectivity solution. Massive Networks will place you in the driver's seat by exposing how you can extend your LAN from any location to include any cloud platform through an advanced high-performance connection that is secure and dedicated to your business-critical data. In his session at 21st Cloud Expo, Paul Mako, CEO & CIO of Massive Networks, wil...
When shopping for a new data processing platform for IoT solutions, many development teams want to be able to test-drive options before making a choice. Yet when evaluating an IoT solution, it’s simply not feasible to do so at scale with physical devices. Building a sensor simulator is the next best choice; however, generating a realistic simulation at very high TPS with ease of configurability is a formidable challenge. When dealing with multiple application or transport protocols, you would be...
Deep learning has been very successful in social sciences and specially areas where there is a lot of data. Trading is another field that can be viewed as social science with a lot of data. With the advent of Deep Learning and Big Data technologies for efficient computation, we are finally able to use the same methods in investment management as we would in face recognition or in making chat-bots. In his session at 20th Cloud Expo, Gaurav Chakravorty, co-founder and Head of Strategy Development ...
The goal of Continuous Testing is to shift testing left to find defects earlier and release software faster. This can be achieved by integrating a set of open source functional and performance testing tools in the early stages of your software delivery lifecycle. There is one process that binds all application delivery stages together into one well-orchestrated machine: Continuous Testing. Continuous Testing is the conveyer belt between the Software Factory and production stages. Artifacts are m...
As businesses adopt functionalities in cloud computing, it’s imperative that IT operations consistently ensure cloud systems work correctly – all of the time, and to their best capabilities. In his session at @BigDataExpo, Bernd Harzog, CEO and founder of OpsDataStore, presented an industry answer to the common question, “Are you running IT operations as efficiently and as cost effectively as you need to?” He then expounded on the industry issues he frequently came up against as an analyst, and ...
Cloud resources, although available in abundance, are inherently volatile. For transactional computing, like ERP and most enterprise software, this is a challenge as transactional integrity and data fidelity is paramount – making it a challenge to create cloud native applications while relying on RDBMS. In his session at 21st Cloud Expo, Claus Jepsen, Chief Architect and Head of Innovation Labs at Unit4, will explore that in order to create distributed and scalable solutions ensuring high availa...
SYS-CON Events announced today that App2Cloud will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. App2Cloud is an online Platform, specializing in migrating legacy applications to any Cloud Providers (AWS, Azure, Google Cloud).
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., discussed how these tools can be leveraged to develop a lasting competitive advantage ...